Save information for later
Sign Up

Learn About Progressive Supranuclear Palsy Atypical

What are the alternative names for Progressive Supranuclear Palsy Atypical?
  • Progressive supranuclear palsy atypical
  • Atypical PSP
Who are the top Progressive Supranuclear Palsy Atypical Local Doctors?

Geisinger Clinic

100 N Academy Ave, 
Danville, PA 
 62.5 mi
Offers Telehealth

Kenny Schwartz is a Neurologist in Danville, Pennsylvania. Dr. Schwartz and is rated as a Distinguished provider by MediFind in the treatment of Progressive Supranuclear Palsy Atypical. His top areas of expertise are Supranuclear Ocular Palsy, Progressive Supranuclear Palsy, Supranuclear Ophthalmoplegia, and Progressive Supranuclear Palsy Atypical.

Internal Medicine
Internal Medicine

Geisinger Clinic

660 Baltimore Dr, 
Wilkes Barre, PA 
 27.4 mi

Samuel Valenti is an Internal Medicine provider in Wilkes Barre, Pennsylvania. Dr. Valenti and is rated as an Experienced provider by MediFind in the treatment of Progressive Supranuclear Palsy Atypical. His top areas of expertise are Poliomyelitis, Protein Deficiency, Acute Kidney Failure, and Parkinson's Disease.

 
 
 
 
Learn about our expert tiers
Learn More
Internal Medicine
Internal Medicine

Commonwealth Physician Network LLC

4 E Main St, 
Nanticoke, PA 
 31.3 mi
Offers Telehealth

David Mouallem is an Internal Medicine provider in Nanticoke, Pennsylvania. Dr. Mouallem and is rated as an Experienced provider by MediFind in the treatment of Progressive Supranuclear Palsy Atypical. His top areas of expertise are Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Hypertension, Endoscopy, and Pacemaker Implantation.

What are the latest Progressive Supranuclear Palsy Atypical Clinical Trials?
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)

Summary: PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.

Match to trials
Find the right clinical trials for you in under a minute
Get started
The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism

Summary: Progressive supranuclear palsy (PSP), Multiple system atrophy (MSA) and corticobasal syndrome (CBS) are severe neurodegenerative diseases with rapid progression and no effective treatment. Patients quickly succumb to increasing motor and non-motor symptoms and survival ranges from \ 3 years to \ 10 years. Although PSP, MSA and CBS are rare diseases they constitute a major and mostly unaddressed ch...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center